Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women

Background: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection. Methods:Women (1,788) ages 16 to 23 years underwent cytologic testing and PCR-based testing of cervical swab...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2010
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23631
Acceso en línea:
https://doi.org/10.1158/1055-9965.EPI-09-1235
https://repository.urosario.edu.co/handle/10336/23631
Palabra clave:
Adolescent
Adult
Article
Clinical feature
Clinical trial
Controlled study
Cytology
Disease classification
Disease duration
Female
Human
Human tissue
Incidence
Major clinical study
Papillomavirus infection
Polymerase chain reaction
Priority journal
Uterine cervix
Double blind procedure
Genetics
Isolation and purification
Papilloma virus
Papillomavirus infections
Phase 3 clinical trial (topic)
Prevalence
Randomized controlled trial (topic)
Uterine cervical diseases
Virology
Young adult
Virus dna
Adolescent
Double-blind method
Female
Humans
Incidence
Papillomaviridae
Papillomavirus infections
Polymerase chain reaction
Prevalence
Randomized controlled trials as topic
Uterine cervical diseases
Young adult
phase iii as topic
viral
Clinical trials
Dna
Rights
License
Abierto (Texto Completo)
Description
Summary:Background: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection. Methods:Women (1,788) ages 16 to 23 years underwent cytologic testing and PCR-based testing of cervical swab samples for HPV DNA (HPV-16/18/31/33/35/45/52/58/59) at ?6-month intervals for up to 4 years in the context of a phase 3 clinical trial (placebo arm). HPV type - specific incidence rates were estimated per 100 person-years. Duration of type-specific cervical infection episodes and risk of reappearance following a period of nondetection were estimated using Kaplan-Meier methods. Results: HPV-16 exhibited the highest (5.9), and HPV-35 and HPV-33 exhibited the lowest (1.0) incidence rates per 100 person-years. Mean cervical infection durations ranged from 13 months for HPV-59 to 20 months for HPV-16 and 58 (with ongoing infections censored at the time of treatment, if done). The risk of cervical infection reappearance within ?3 years following a period of nondetection ranged from 0% to 16% across HPV types, with a mean of 8%. Limited evidence was found for a role of false-positive HPV tests, missed infections that were above the threshold for detection, or new acquisition of infection in accounting for patterns of infection reappearance. Conclusions: Incidence of high-risk cervical infection was observed to vary considerably more across HPV types than infection duration. A nontrivial proportion of women exhibited infection reappearance following a period of nondetection, with a potential explanation for many such events observed within this analysis being a return to detectable levels of a previously acquired infection. Impact: The risk of HPV infection reappearance following a period of nondetection has not been previously reported for individual HPV types, and this study finds that a nontrivial proportion of infected women exhibit reappearances. Future studies could ascertain subject-level factors that potentially modify the risk of infection reappearance. ©2010 AACR.